Holly Soutter

Holly Soutter is a distinguished professional in the field of scientific business analysis and drug discovery, currently serving as a Principal Scientific Business Analyst at TetraScience since November 2025. Soutter has an extensive background, including roles at the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, where leadership in assay development and drug discovery projects was exemplified. Prior experiences include contributing to critical drug developments at Silicon Therapeutics and X-Chem, Inc., as well as playing a significant role at Pfizer in the discovery of an IRAK4 inhibitor. Additionally, foundational research was conducted at institutions such as the Scripps Research Institute and Abbott Bioresearch Center, leading to advancements in structural biology and antibody development. Soutter's academic credentials include a Ph.D. in Chemistry from Clark University and a B.A. in Chemistry from Hunter College.